Farms.com Home   Ag Industry News

American Soybean Association responds to New York Times article

Article says GMO usage doesn’t equal higher yields

By Diego Flammini
Assistant Editor, North American Content
Farms.com

The American Soybean Association (ASA) responded to a recent New York Times article that says GMO use in North America hasn’t increased crop yields or reduced pesticide use.

“In the interest of a fair and honest discussion of this issue, we have to confront the inaccuracies and false conclusions of the article,” ASA said in a release.

In the Times article, the author states when there’s no advantage in the use of GMOs in food per acre in Canada or the United States. The author compared the findings to countries like Germany and France, and used United Nations data.

The ASA said the reporter only included what he felt was necessary to his argument.

“In his interpretation of the data, the author fails to standardize the data from France when comparing it to similar data from the U.S., where we have more than 9 times the amount of arable land.”

The ASA agreed that GMOs aren’t a “silver bullet” for agriculture, but says the reporter didn’t give producers credit for adapting their operations.

“The article also lacks any mention of reduced or eliminated tillage as a result of increased use of GMOs on American soybean operations. Our farmers live on their land, drink from the wells, and rely on productive soil that will yield for their children and grandchildren as well. GMO technology provides for weed control without tilling the soil multiple times. This has dramatically increased the use of conservation tillage, reduced soil erosion, improved water quality, and reduced greenhouse gas emissions.”


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.